Description General description An orally available, stable, pyrazolone derivative that acts as a potent prototypic agonist of human formyl-peptide-like 1 receptor (hFPRL1; FPR2) (EC50 = 44 nM). Also shown to block polymorphonuclear neutrophil (PMN) migration in a dose-dependent manner, irrespective of the type of stimulant applied. Reported to act by activating extracellular loop I, while the downstream signaling effects are attributed to its loop II region. Does not affect several other protein targets studied, such as p38a, CXCR2, histamine receptor, and TRPV1 (~10 mM). Exhibit suitable pharmacokinetic properties, such as low clearance (126 ml/h/kg) and a half-life of ~2.78 hours. Shown to significantly reduce edema in mouse ear (~50 mg/kg) following oral administration. Packaging 10 mg in Glass bottle Packaged under inert gas Warning Toxicity: Standard Handling (A) Reconstitution Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C. Other Notes Bena, S., et al. 2012, J Biol Chem287, 24690. Burli, R. W, et al. 2006, Bioorg Med Chem Lett.16, 3713.; Description